1-3 of 3
Peter Ho
Close
Sort by
Journal Articles

Discovery of Candidate Predictors of Response to Tazemetostat in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma Using NGS Technology on ctDNA Samples Collected Pre-Treatment

Scott Daigle, Alice A. McDonald, BA, Franck Morschhauser, MD PhD, Gilles Salles, MD, Vincent Ribrag, Pamela McKay, Herve Tilly, Anna Schmitt, John Gerecitano, MD PhD, Christophe Fruchart, MD, Peter Johnson, MD FRCP, John Radford, MD, Michael J. Dickinson, Charles Herbaux, Stephen Opat, FRACP, FRCPA, Wojciech Jurczak, PhDMD, Guillaume Cartron, Thierry Lamy, Pr, MD PhD, Pier Luigi Zinzani, MD, Sarit Assouline, MD, Ryan D. Morin, PhDBSc,MSc, Helen Wu, Mark Sausen, Alicia Clawson, Peter Ho, Harry Miao, Stephen Blakemore
Journal: Blood
Blood (2017) 130 (Supplement 1): 4013.
https://doi.org/10.1182/blood.V130.Suppl_1.4013.4013
Published: 2017
Journal Articles

Response to the EZH2 Inhibitor Tazemetostat Is Independent of Cell of Origin Determined Via Hans Imunohistochemistry or Nanostring Lymphoma Subtyping Test in EZH2 Wild-Type DLBCL Patients

Alice A. McDonald, BA, Franck Morschhauser, MD PhD, Vincent Ribrag, Pamela McKay, Gilles Salles, MD PhD, Herve Tilly, Anna Schmitt, John Gerecitano, MD PhD, Michael J. Dickinson, Sarit Assouline, MD, Corinne Haioun, John G. Gribben, MDDSc FMedSci, Pier Luigi Zinzani, MD, Helen Wu, Steven Kussick, James Storhoff, PhD, John Larus, Alicia Clawson, Adlai Grayson, Scott Daigle, Peter Ho, Harry Miao, Stephen Blakemore
Journal: Blood
Blood (2017) 130 (Supplement 1): 2745.
https://doi.org/10.1182/blood.V130.Suppl_1.2745.2745
Published: 2017
Journal Articles

A Phase I Study To Investigate the Pharmacokinetics (PK) and Pharmacodynamics (PD) of an Oral Platelet Growth Factor (SB-559448) in Healthy Subjects.

Sheng-Fang Su, PhD, Bin Peng, MD, PhD, Daphne Williams, Jung Wook Park, Malcolm L. Handel, BSc, MB BS, PhD, Julian Jenkins, MS, Peter Ho, MD, PhD
Journal: Blood
Blood (2006) 108 (11): 1072.
https://doi.org/10.1182/blood.V108.11.1072.1072
Published: 2006